VERTEX PHARMACEUTICALS INC / MA

Drug pipeline (23)

Asset	Stage	Revenue	Trials	Status
TRIKAFTA (COPACKAGED)	approved	$2.5B*Q2 2026	103	approved
ALYFTREK	approved	$573.6M*Q2 2026	60	approved
KALYDECO	approved	$112.4MQ4 2023	89	approved
CASGEVY	approved	$76.4MQ2 2026	6	approved
JOURNAVX	approved	$49.6MQ2 2026	26	approved

Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.

Clinical trials (246)

NCT ID	Phase	Status	Start	Completion	Sponsor name	Title
NCT01590459	phase2	completed	2012-04-01	2014-07-01	Vertex Pharmaceuticals Incorporated	24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate
NCT01052194	phase2	completed	2010-02-01	2011-07-01	Vertex Pharmaceuticals Incorporated	A 12-week Study of 4 Doses of VX-509 in Subjects With Active Rheumatoid Arthritis
NCT03764072	phase2	completed	2018-12-12	2019-01-17	Vertex Pharmaceuticals Incorporated	A Dose-ranging Study to Evaluate Efficacy and Safety of VX-150 in Subjects With Acute Pain Following Bunionectomy
NCT04208529	phase3	enrolling_by_invitation	2021-01-20	2039-09-30	Vertex Pharmaceuticals Incorporated	A Long-term Follow-up Study in Participants Who Received CTX001
NCT01754935	phase2	completed	2013-01-01	2014-01-01	Vertex Pharmaceuticals Incorporated	A Magnetic Resonance Imaging Study and Arthroscopic Biopsy Substudy in Subjects With Active Rheumatoid Arthritis Receiving VX-509, an Oral JAK3 Inhibitor

FDA applications (11)

Application

Approved

Type

Applicant

Products

NDA 219209

2025-01-30

NDA

VERTEX PHARMACEUTICALS INC

NDA 218730

2024-12-20

NDA

VERTEX PHARMACEUTICALS INC

BLA 125787

2023-12-08

BLA

VERTEX PHARMACEUTICALS INC

NDA 217660

2023-04-26

NDA

VERTEX PHARMACEUTICALS INC

NDA 212273

2019-10-21

NDA

VERTEX PHARMACEUTICALS INC